Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
Author:
Pratedrat Pornpitra12ORCID, Intharasongkroh Duangnapa3, Chansaenroj Jira1, Vichaiwattana Preeyaporn1, Srimuan Donchida1, Thatsanatorn Thaksaporn1, Klinfueng Sirapa1, Nilyanimit Pornjarim1ORCID, Chirathaworn Chintana4, Kupatawintu Pawinee3, Chaiwanichsiri Dootchai3, Wanlapakorn Nasamon1, Poovorawan Yong15ORCID
Affiliation:
1. Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand 2. Department of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand 3. National Blood Centre, Thai Red Cross Society, Bangkok 10330, Thailand 4. Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand 5. Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand
Abstract
Coronavirus disease 2019 (COVID-19) is a contagious illness worldwide. While guidelines for the treatment of COVID-19 have been established, the understanding of the relationship among neutralizing antibodies, cytokines, and the combined use of antiviral medications, steroid drugs, and convalescent plasma therapy remains limited. Here, we investigated the connection between the immunological response and the efficacy of convalescent plasma therapy in COVID-19 patients with moderate-to-severe pneumonia. The study included a retrospective analysis of 49 patients aged 35 to 57. We conducted clinical assessments to determine antibody levels, biochemical markers, and cytokine levels. Among the patients, 48 (98%) were discharged, while one died. We observed significantly higher levels of anti-nucleocapsid, anti-spike, and neutralizing antibodies on days 3, 7, and 14 after the transfusion compared to before treatment. Serum CRP and D-dimer levels varied significantly across these four time points. Moreover, convalescent plasma therapy demonstrated an immunoregulatory effect on cytokine parameters, with significant differences in IFN-β, IL-6, IL-10, and IFN-α levels observed at different sampling times. Evaluating the cytokine signature, along with standard clinical and laboratory parameters, may help to identify the onset of a cytokine storm in COVID-19 patients and determine the appropriate indication for anti-cytokine treatment.
Funder
Health Systems Research Institute National Research Council of Thailand Center of Excellence in Clinical Virology Chulalongkorn University King Chulalongkorn Memorial Hospital
Reference39 articles.
1. Ghayda, R.A., Lee, J., Lee, J.Y., Kim, D.K., Lee, K.H., Hong, S.H., Han, Y.J., Kim, J.S., Yang, J.W., and Kronbichler, A. (2020). Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 17. 2. Grant, M.C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E.L., and Wade, R.G. (2020). The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS ONE, 15. 3. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study;Chen;Lancet,2020 4. Risk factors for severe and critically ill COVID-19 patients: A review;Gao;Allergy,2021 5. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort;Fumeaux;EClinicalMedicine,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|